Skip to ContentSkip to Navigation
Rijksuniversiteit Groningenfounded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons R.A. (Rudolf) de Boer
University Medical Center Groningen

R.A. (Rudolf) de Boer

Cardioloog & Hoofd Experimentele Cardiologie

Publicaties

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

Age-related penetrance of phospholamban p.Arg14del cardiomyopathy

Albuminuria is associated with increased risk of dementia, independent of eGFR: The SCREAM project

Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction

Associations of Genetically Predicted CKD With Urinary Tract Cancer and Lung Cancer: A Mendelian Randomization Analysis

Beyond the gut: Systemic levels of short-chain fatty acids are altered in patients with heart failure

Bone morphogenetic protein 10: clinical correlates and risk of incident atrial fibrillation

Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer

Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity

Circulating bmp10 (bone morphogenic protein 10) in the assessment of congestion and pulmonary hypertension

Pers/media

ESC-congres 2023 Gesprek van de dag | Hartfalen

FOCUS: praktische overwegingen bij starten van SGLT2-remmers bij hartfalen

De nieuwe ESC-hartfalenrichtlijn 2021 in het kort

Eerste kunsthart in Nederland geplaatst bij 54-jarige man

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

Nier- en HF-uitkomsten met SGLT2-remmer in het gehele EF spectrum in HF

Dr Rudolf de Boer Discusses Encouraging Trial Results on SGLT2 Use in HFpEF

Effecten van SGLT2-remmers in vogelvlucht

Margreet Westerhof heeft de noordelijke hartziekte PLN: 'Je leeft met een tijdbom'